Company intelligence / Profile preview

Amersham Biosciences

Little Chalfont, Buckinghamshire, United Kingdom

Ownership: Private
Employees: ~10000
Development stage: Other

Overview

Amersham Biosciences was a premier global provider of integrated systems and solutions for disease research, drug development, and manufacture. The company was particularly renowned for its leadership in proteomics and genomics, offering industry-standard products such as the ÄKTA chromatography systems and Sephadex purification resins. Originally formed as a joint venture between Amersham plc and Pharmacia, it became a cornerstone of the life sciences tools market before its acquisition by GE Healthcare in 2004. Its legacy continues today as a major component of Cytiva, following Danaher's acquisition of GE's life sciences division.

Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Amersham Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amersham Biosciences.

Explore the full profile